Doximity, Inc.
Doximity, Inc. DOCS Peers
See (DOCS) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Healthcare Information Services Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| DOCS | $59.38 | -1.44% | 11.2B | 53.52 | $1.11 | N/A |
| VEEV | $285.20 | +1.49% | 46.6B | 60.59 | $4.71 | N/A |
| GEHC | $76.49 | +3.13% | 35B | 16.07 | $4.76 | +0.17% |
| GEHCV | $56.00 | -4.08% | 25.5B | N/A | N/A | +0.17% |
| SGFY | $30.49 | +0.07% | 8.9B | 70.91 | $0.43 | N/A |
| HQY | $97.41 | +0.34% | 8.4B | 71.10 | $1.37 | N/A |
| RCM | $14.31 | N/A | 6B | -102.21 | -$0.14 | N/A |
| BTSG | $20.15 | +2.23% | 3.5B | 74.63 | $0.27 | N/A |
| BTSGU | $70.45 | -0.01% | 3.5B | N/A | N/A | N/A |
| ONEM | $16.47 | +0.00% | 3.4B | -7.77 | -$2.12 | N/A |
Stock Comparison
DOCS vs VEEV Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, VEEV has a market cap of 46.6B. Regarding current trading prices, DOCS is priced at $59.38, while VEEV trades at $285.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas VEEV's P/E ratio is 60.59. In terms of profitability, DOCS's ROE is +0.22%, compared to VEEV's ROE of +0.14%. Regarding short-term risk, DOCS is more volatile compared to VEEV. This indicates potentially higher risk in terms of short-term price fluctuations for DOCS.
DOCS vs GEHC Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, GEHC has a market cap of 35B. Regarding current trading prices, DOCS is priced at $59.38, while GEHC trades at $76.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas GEHC's P/E ratio is 16.07. In terms of profitability, DOCS's ROE is +0.22%, compared to GEHC's ROE of +0.26%. Regarding short-term risk, DOCS is less volatile compared to GEHC. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.
DOCS vs GEHCV Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, GEHCV has a market cap of 25.5B. Regarding current trading prices, DOCS is priced at $59.38, while GEHCV trades at $56.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas GEHCV's P/E ratio is N/A. In terms of profitability, DOCS's ROE is +0.22%, compared to GEHCV's ROE of +0.26%. Regarding short-term risk, DOCS is less volatile compared to GEHCV. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.
DOCS vs SGFY Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, SGFY has a market cap of 8.9B. Regarding current trading prices, DOCS is priced at $59.38, while SGFY trades at $30.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas SGFY's P/E ratio is 70.91. In terms of profitability, DOCS's ROE is +0.22%, compared to SGFY's ROE of -0.15%. Regarding short-term risk, DOCS is more volatile compared to SGFY. This indicates potentially higher risk in terms of short-term price fluctuations for DOCS.
DOCS vs HQY Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, HQY has a market cap of 8.4B. Regarding current trading prices, DOCS is priced at $59.38, while HQY trades at $97.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas HQY's P/E ratio is 71.10. In terms of profitability, DOCS's ROE is +0.22%, compared to HQY's ROE of +0.06%. Regarding short-term risk, DOCS is more volatile compared to HQY. This indicates potentially higher risk in terms of short-term price fluctuations for DOCS.
DOCS vs RCM Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, RCM has a market cap of 6B. Regarding current trading prices, DOCS is priced at $59.38, while RCM trades at $14.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas RCM's P/E ratio is -102.21. In terms of profitability, DOCS's ROE is +0.22%, compared to RCM's ROE of -0.02%. Regarding short-term risk, DOCS is more volatile compared to RCM. This indicates potentially higher risk in terms of short-term price fluctuations for DOCS.
DOCS vs BTSG Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, BTSG has a market cap of 3.5B. Regarding current trading prices, DOCS is priced at $59.38, while BTSG trades at $20.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas BTSG's P/E ratio is 74.63. In terms of profitability, DOCS's ROE is +0.22%, compared to BTSG's ROE of +0.03%. Regarding short-term risk, DOCS is less volatile compared to BTSG. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.
DOCS vs BTSGU Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, BTSGU has a market cap of 3.5B. Regarding current trading prices, DOCS is priced at $59.38, while BTSGU trades at $70.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas BTSGU's P/E ratio is N/A. In terms of profitability, DOCS's ROE is +0.22%, compared to BTSGU's ROE of +0.03%. Regarding short-term risk, DOCS is more volatile compared to BTSGU. This indicates potentially higher risk in terms of short-term price fluctuations for DOCS.
DOCS vs ONEM Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, ONEM has a market cap of 3.4B. Regarding current trading prices, DOCS is priced at $59.38, while ONEM trades at $16.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas ONEM's P/E ratio is -7.77. In terms of profitability, DOCS's ROE is +0.22%, compared to ONEM's ROE of -0.24%. Regarding short-term risk, DOCS is less volatile compared to ONEM. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.
DOCS vs PRVA Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, PRVA has a market cap of 2.4B. Regarding current trading prices, DOCS is priced at $59.38, while PRVA trades at $20.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas PRVA's P/E ratio is 167.33. In terms of profitability, DOCS's ROE is +0.22%, compared to PRVA's ROE of +0.02%. Regarding short-term risk, DOCS is more volatile compared to PRVA. This indicates potentially higher risk in terms of short-term price fluctuations for DOCS.
DOCS vs WGS Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, WGS has a market cap of 2.3B. Regarding current trading prices, DOCS is priced at $59.38, while WGS trades at $80.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas WGS's P/E ratio is -58.20. In terms of profitability, DOCS's ROE is +0.22%, compared to WGS's ROE of -0.17%. Regarding short-term risk, DOCS is less volatile compared to WGS. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.
DOCS vs PGNY Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, PGNY has a market cap of 2B. Regarding current trading prices, DOCS is priced at $59.38, while PGNY trades at $22.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas PGNY's P/E ratio is 40.32. In terms of profitability, DOCS's ROE is +0.22%, compared to PGNY's ROE of +0.12%. Regarding short-term risk, DOCS is more volatile compared to PGNY. This indicates potentially higher risk in terms of short-term price fluctuations for DOCS.
DOCS vs GDRX Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, GDRX has a market cap of 1.8B. Regarding current trading prices, DOCS is priced at $59.38, while GDRX trades at $4.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas GDRX's P/E ratio is 70.29. In terms of profitability, DOCS's ROE is +0.22%, compared to GDRX's ROE of +0.07%. Regarding short-term risk, DOCS is less volatile compared to GDRX. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.
DOCS vs PINC Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, PINC has a market cap of 1.7B. Regarding current trading prices, DOCS is priced at $59.38, while PINC trades at $21.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas PINC's P/E ratio is 20.71. In terms of profitability, DOCS's ROE is +0.22%, compared to PINC's ROE of +0.03%. Regarding short-term risk, DOCS is more volatile compared to PINC. This indicates potentially higher risk in terms of short-term price fluctuations for DOCS.
DOCS vs CERT Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, CERT has a market cap of 1.7B. Regarding current trading prices, DOCS is priced at $59.38, while CERT trades at $10.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas CERT's P/E ratio is -531.00. In terms of profitability, DOCS's ROE is +0.22%, compared to CERT's ROE of -0.00%. Regarding short-term risk, DOCS is less volatile compared to CERT. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.
DOCS vs SDGR Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, SDGR has a market cap of 1.7B. Regarding current trading prices, DOCS is priced at $59.38, while SDGR trades at $22.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas SDGR's P/E ratio is -8.66. In terms of profitability, DOCS's ROE is +0.22%, compared to SDGR's ROE of -0.45%. Regarding short-term risk, DOCS is less volatile compared to SDGR. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.
DOCS vs TXG Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, TXG has a market cap of 1.6B. Regarding current trading prices, DOCS is priced at $59.38, while TXG trades at $12.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas TXG's P/E ratio is -10.15. In terms of profitability, DOCS's ROE is +0.22%, compared to TXG's ROE of -0.22%. Regarding short-term risk, DOCS is less volatile compared to TXG. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.
DOCS vs NXGN Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, NXGN has a market cap of 1.6B. Regarding current trading prices, DOCS is priced at $59.38, while NXGN trades at $23.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas NXGN's P/E ratio is -266.00. In terms of profitability, DOCS's ROE is +0.22%, compared to NXGN's ROE of -0.01%. Regarding short-term risk, DOCS is more volatile compared to NXGN. This indicates potentially higher risk in terms of short-term price fluctuations for DOCS.
DOCS vs PHR Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, PHR has a market cap of 1.6B. Regarding current trading prices, DOCS is priced at $59.38, while PHR trades at $26.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas PHR's P/E ratio is -36.22. In terms of profitability, DOCS's ROE is +0.22%, compared to PHR's ROE of -0.16%. Regarding short-term risk, DOCS is more volatile compared to PHR. This indicates potentially higher risk in terms of short-term price fluctuations for DOCS.
DOCS vs TDOC Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, TDOC has a market cap of 1.5B. Regarding current trading prices, DOCS is priced at $59.38, while TDOC trades at $8.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas TDOC's P/E ratio is -1.42. In terms of profitability, DOCS's ROE is +0.22%, compared to TDOC's ROE of -0.68%. Regarding short-term risk, DOCS is less volatile compared to TDOC. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.
DOCS vs AGTI Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, AGTI has a market cap of 1.4B. Regarding current trading prices, DOCS is priced at $59.38, while AGTI trades at $10.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas AGTI's P/E ratio is -71.79. In terms of profitability, DOCS's ROE is +0.22%, compared to AGTI's ROE of -0.01%. Regarding short-term risk, DOCS is more volatile compared to AGTI. This indicates potentially higher risk in terms of short-term price fluctuations for DOCS.
DOCS vs OMCL Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, OMCL has a market cap of 1.3B. Regarding current trading prices, DOCS is priced at $59.38, while OMCL trades at $28.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas OMCL's P/E ratio is 61.43. In terms of profitability, DOCS's ROE is +0.22%, compared to OMCL's ROE of +0.02%. Regarding short-term risk, DOCS is less volatile compared to OMCL. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.
DOCS vs EVH Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, EVH has a market cap of 1.1B. Regarding current trading prices, DOCS is priced at $59.38, while EVH trades at $9.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas EVH's P/E ratio is -7.95. In terms of profitability, DOCS's ROE is +0.22%, compared to EVH's ROE of -0.11%. Regarding short-term risk, DOCS is less volatile compared to EVH. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.
DOCS vs HSTM Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, HSTM has a market cap of 812.3M. Regarding current trading prices, DOCS is priced at $59.38, while HSTM trades at $26.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas HSTM's P/E ratio is 42.24. In terms of profitability, DOCS's ROE is +0.22%, compared to HSTM's ROE of +0.05%. Regarding short-term risk, DOCS is more volatile compared to HSTM. This indicates potentially higher risk in terms of short-term price fluctuations for DOCS.
DOCS vs CTEV Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, CTEV has a market cap of 701.8M. Regarding current trading prices, DOCS is priced at $59.38, while CTEV trades at $42.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas CTEV's P/E ratio is -0.59. In terms of profitability, DOCS's ROE is +0.22%, compared to CTEV's ROE of -5.18%. Regarding short-term risk, DOCS is less volatile compared to CTEV. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.
DOCS vs SY Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, SY has a market cap of 694.4M. Regarding current trading prices, DOCS is priced at $59.38, while SY trades at $5.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas SY's P/E ratio is -6.58. In terms of profitability, DOCS's ROE is +0.22%, compared to SY's ROE of -0.28%. Regarding short-term risk, DOCS is less volatile compared to SY. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.
DOCS vs MPLN-WT Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, MPLN-WT has a market cap of 625.2M. Regarding current trading prices, DOCS is priced at $59.38, while MPLN-WT trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas MPLN-WT's P/E ratio is N/A. In terms of profitability, DOCS's ROE is +0.22%, compared to MPLN-WT's ROE of -5.18%. Regarding short-term risk, DOCS is less volatile compared to MPLN-WT. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.
DOCS vs ACCD Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, ACCD has a market cap of 575.6M. Regarding current trading prices, DOCS is priced at $59.38, while ACCD trades at $7.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas ACCD's P/E ratio is -3.08. In terms of profitability, DOCS's ROE is +0.22%, compared to ACCD's ROE of -0.45%. Regarding short-term risk, DOCS is more volatile compared to ACCD. This indicates potentially higher risk in terms of short-term price fluctuations for DOCS.
DOCS vs NUTX Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, NUTX has a market cap of 555.6M. Regarding current trading prices, DOCS is priced at $59.38, while NUTX trades at $100.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas NUTX's P/E ratio is 8.10. In terms of profitability, DOCS's ROE is +0.22%, compared to NUTX's ROE of +0.71%. Regarding short-term risk, DOCS is less volatile compared to NUTX. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.
DOCS vs SHCR Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, SHCR has a market cap of 531.8M. Regarding current trading prices, DOCS is priced at $59.38, while SHCR trades at $1.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas SHCR's P/E ratio is -3.76. In terms of profitability, DOCS's ROE is +0.22%, compared to SHCR's ROE of -0.24%. Regarding short-term risk, DOCS is more volatile compared to SHCR. This indicates potentially higher risk in terms of short-term price fluctuations for DOCS.
DOCS vs DH Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, DH has a market cap of 440.1M. Regarding current trading prices, DOCS is priced at $59.38, while DH trades at $4.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas DH's P/E ratio is -0.93. In terms of profitability, DOCS's ROE is +0.22%, compared to DH's ROE of -1.07%. Regarding short-term risk, DOCS is less volatile compared to DH. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.
DOCS vs SLGCW Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, SLGCW has a market cap of 396.2M. Regarding current trading prices, DOCS is priced at $59.38, while SLGCW trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas SLGCW's P/E ratio is -0.16. In terms of profitability, DOCS's ROE is +0.22%, compared to SLGCW's ROE of -0.19%. Regarding short-term risk, DOCS is less volatile compared to SLGCW. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.
DOCS vs SLGC Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, SLGC has a market cap of 396.2M. Regarding current trading prices, DOCS is priced at $59.38, while SLGC trades at $2.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas SLGC's P/E ratio is -3.04. In terms of profitability, DOCS's ROE is +0.22%, compared to SLGC's ROE of -0.19%. Regarding short-term risk, DOCS is less volatile compared to SLGC. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.
DOCS vs MPLN Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, MPLN has a market cap of 375M. Regarding current trading prices, DOCS is priced at $59.38, while MPLN trades at $23.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas MPLN's P/E ratio is -0.23. In terms of profitability, DOCS's ROE is +0.22%, compared to MPLN's ROE of -5.18%. Regarding short-term risk, DOCS is less volatile compared to MPLN. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.
DOCS vs SPOK Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, SPOK has a market cap of 361.5M. Regarding current trading prices, DOCS is priced at $59.38, while SPOK trades at $17.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas SPOK's P/E ratio is 22.82. In terms of profitability, DOCS's ROE is +0.22%, compared to SPOK's ROE of +0.10%. Regarding short-term risk, DOCS is more volatile compared to SPOK. This indicates potentially higher risk in terms of short-term price fluctuations for DOCS.
DOCS vs TBRG Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, TBRG has a market cap of 336.1M. Regarding current trading prices, DOCS is priced at $59.38, while TBRG trades at $22.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas TBRG's P/E ratio is -18.04. In terms of profitability, DOCS's ROE is +0.22%, compared to TBRG's ROE of -0.10%. Regarding short-term risk, DOCS is more volatile compared to TBRG. This indicates potentially higher risk in terms of short-term price fluctuations for DOCS.
DOCS vs NRC Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, NRC has a market cap of 322.6M. Regarding current trading prices, DOCS is priced at $59.38, while NRC trades at $14.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas NRC's P/E ratio is 13.88. In terms of profitability, DOCS's ROE is +0.22%, compared to NRC's ROE of +0.71%. Regarding short-term risk, DOCS is more volatile compared to NRC. This indicates potentially higher risk in terms of short-term price fluctuations for DOCS.
DOCS vs TRHC Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, TRHC has a market cap of 284M. Regarding current trading prices, DOCS is priced at $59.38, while TRHC trades at $10.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas TRHC's P/E ratio is -4.27. In terms of profitability, DOCS's ROE is +0.22%, compared to TRHC's ROE of +121.31%. Regarding short-term risk, DOCS is more volatile compared to TRHC. This indicates potentially higher risk in terms of short-term price fluctuations for DOCS.
DOCS vs HCAT Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, HCAT has a market cap of 274.2M. Regarding current trading prices, DOCS is priced at $59.38, while HCAT trades at $3.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas HCAT's P/E ratio is -3.43. In terms of profitability, DOCS's ROE is +0.22%, compared to HCAT's ROE of -0.20%. Regarding short-term risk, DOCS is less volatile compared to HCAT. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.
DOCS vs SLP Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, SLP has a market cap of 262.2M. Regarding current trading prices, DOCS is priced at $59.38, while SLP trades at $13.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas SLP's P/E ratio is -4.14. In terms of profitability, DOCS's ROE is +0.22%, compared to SLP's ROE of -0.37%. Regarding short-term risk, DOCS is less volatile compared to SLP. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.
DOCS vs SMFR Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, SMFR has a market cap of 246.4M. Regarding current trading prices, DOCS is priced at $59.38, while SMFR trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas SMFR's P/E ratio is N/A. In terms of profitability, DOCS's ROE is +0.22%, compared to SMFR's ROE of -0.17%. Regarding short-term risk, DOCS is less volatile compared to SMFR. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.
DOCS vs OPRX Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, OPRX has a market cap of 246M. Regarding current trading prices, DOCS is priced at $59.38, while OPRX trades at $13.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas OPRX's P/E ratio is -15.83. In terms of profitability, DOCS's ROE is +0.22%, compared to OPRX's ROE of -0.13%. Regarding short-term risk, DOCS is less volatile compared to OPRX. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.
DOCS vs SOPH Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, SOPH has a market cap of 229.2M. Regarding current trading prices, DOCS is priced at $59.38, while SOPH trades at $3.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas SOPH's P/E ratio is -3.43. In terms of profitability, DOCS's ROE is +0.22%, compared to SOPH's ROE of -0.63%. Regarding short-term risk, DOCS is less volatile compared to SOPH. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.
DOCS vs CPSI Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, CPSI has a market cap of 133.7M. Regarding current trading prices, DOCS is priced at $59.38, while CPSI trades at $9.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas CPSI's P/E ratio is -183.80. In terms of profitability, DOCS's ROE is +0.22%, compared to CPSI's ROE of -0.18%. Regarding short-term risk, DOCS is less volatile compared to CPSI. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.
DOCS vs AMWL Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, AMWL has a market cap of 130.9M. Regarding current trading prices, DOCS is priced at $59.38, while AMWL trades at $8.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas AMWL's P/E ratio is -0.82. In terms of profitability, DOCS's ROE is +0.22%, compared to AMWL's ROE of -0.48%. Regarding short-term risk, DOCS is less volatile compared to AMWL. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.
DOCS vs AUGX Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, AUGX has a market cap of 115.9M. Regarding current trading prices, DOCS is priced at $59.38, while AUGX trades at $2.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas AUGX's P/E ratio is -4.99. In terms of profitability, DOCS's ROE is +0.22%, compared to AUGX's ROE of -1.13%. Regarding short-term risk, DOCS is more volatile compared to AUGX. This indicates potentially higher risk in terms of short-term price fluctuations for DOCS.
DOCS vs EUDA Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, EUDA has a market cap of 112.2M. Regarding current trading prices, DOCS is priced at $59.38, while EUDA trades at $3.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas EUDA's P/E ratio is -5.59. In terms of profitability, DOCS's ROE is +0.22%, compared to EUDA's ROE of +3.05%. Regarding short-term risk, DOCS is less volatile compared to EUDA. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.
DOCS vs CCLD Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, CCLD has a market cap of 102M. Regarding current trading prices, DOCS is priced at $59.38, while CCLD trades at $2.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas CCLD's P/E ratio is -10.95. In terms of profitability, DOCS's ROE is +0.22%, compared to CCLD's ROE of +0.21%. Regarding short-term risk, DOCS is less volatile compared to CCLD. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.
DOCS vs CCLDO Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, CCLDO has a market cap of 101.1M. Regarding current trading prices, DOCS is priced at $59.38, while CCLDO trades at $20.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas CCLDO's P/E ratio is N/A. In terms of profitability, DOCS's ROE is +0.22%, compared to CCLDO's ROE of +0.21%. Regarding short-term risk, DOCS is more volatile compared to CCLDO. This indicates potentially higher risk in terms of short-term price fluctuations for DOCS.
DOCS vs FORA Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, FORA has a market cap of 60.2M. Regarding current trading prices, DOCS is priced at $59.38, while FORA trades at $1.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas FORA's P/E ratio is -16.08. In terms of profitability, DOCS's ROE is +0.22%, compared to FORA's ROE of -0.13%. Regarding short-term risk, DOCS is less volatile compared to FORA. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.
DOCS vs CCLDP Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, CCLDP has a market cap of 59.9M. Regarding current trading prices, DOCS is priced at $59.38, while CCLDP trades at $19.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas CCLDP's P/E ratio is N/A. In terms of profitability, DOCS's ROE is +0.22%, compared to CCLDP's ROE of +0.21%. Regarding short-term risk, DOCS is more volatile compared to CCLDP. This indicates potentially higher risk in terms of short-term price fluctuations for DOCS.
DOCS vs BEAT Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, BEAT has a market cap of 43.2M. Regarding current trading prices, DOCS is priced at $59.38, while BEAT trades at $1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas BEAT's P/E ratio is -1.73. In terms of profitability, DOCS's ROE is +0.22%, compared to BEAT's ROE of -3.58%. Regarding short-term risk, DOCS is less volatile compared to BEAT. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.
DOCS vs BEATW Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, BEATW has a market cap of 43M. Regarding current trading prices, DOCS is priced at $59.38, while BEATW trades at $0.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas BEATW's P/E ratio is -0.57. In terms of profitability, DOCS's ROE is +0.22%, compared to BEATW's ROE of -3.58%. Regarding short-term risk, DOCS is less volatile compared to BEATW. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.
DOCS vs SNCE Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, SNCE has a market cap of 34.7M. Regarding current trading prices, DOCS is priced at $59.38, while SNCE trades at $5.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas SNCE's P/E ratio is -0.27. In terms of profitability, DOCS's ROE is +0.22%, compared to SNCE's ROE of -0.47%. Regarding short-term risk, DOCS is more volatile compared to SNCE. This indicates potentially higher risk in terms of short-term price fluctuations for DOCS.
DOCS vs AKLI Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, AKLI has a market cap of 34.1M. Regarding current trading prices, DOCS is priced at $59.38, while AKLI trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas AKLI's P/E ratio is -0.71. In terms of profitability, DOCS's ROE is +0.22%, compared to AKLI's ROE of -0.38%. Regarding short-term risk, DOCS is more volatile compared to AKLI. This indicates potentially higher risk in terms of short-term price fluctuations for DOCS.
DOCS vs SHLT Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, SHLT has a market cap of 33.6M. Regarding current trading prices, DOCS is priced at $59.38, while SHLT trades at $2.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas SHLT's P/E ratio is -3.87. In terms of profitability, DOCS's ROE is +0.22%, compared to SHLT's ROE of -0.07%. Regarding short-term risk, DOCS is more volatile compared to SHLT. This indicates potentially higher risk in terms of short-term price fluctuations for DOCS.
DOCS vs SHCRW Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, SHCRW has a market cap of 32.5M. Regarding current trading prices, DOCS is priced at $59.38, while SHCRW trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas SHCRW's P/E ratio is -0.00. In terms of profitability, DOCS's ROE is +0.22%, compared to SHCRW's ROE of -0.24%. Regarding short-term risk, DOCS is less volatile compared to SHCRW. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.
DOCS vs SCNX Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, SCNX has a market cap of 28.9M. Regarding current trading prices, DOCS is priced at $59.38, while SCNX trades at $2.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas SCNX's P/E ratio is 3.33. In terms of profitability, DOCS's ROE is +0.22%, compared to SCNX's ROE of -0.24%. Regarding short-term risk, DOCS is less volatile compared to SCNX. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.
DOCS vs ONMD Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, ONMD has a market cap of 25M. Regarding current trading prices, DOCS is priced at $59.38, while ONMD trades at $0.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas ONMD's P/E ratio is -1.59. In terms of profitability, DOCS's ROE is +0.22%, compared to ONMD's ROE of +0.60%. Regarding short-term risk, DOCS is less volatile compared to ONMD. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.
DOCS vs STRM Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, STRM has a market cap of 23.1M. Regarding current trading prices, DOCS is priced at $59.38, while STRM trades at $5.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas STRM's P/E ratio is -2.39. In terms of profitability, DOCS's ROE is +0.22%, compared to STRM's ROE of -0.68%. Regarding short-term risk, DOCS is more volatile compared to STRM. This indicates potentially higher risk in terms of short-term price fluctuations for DOCS.
DOCS vs RNLX Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, RNLX has a market cap of 22.5M. Regarding current trading prices, DOCS is priced at $59.38, while RNLX trades at $0.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas RNLX's P/E ratio is -0.33. In terms of profitability, DOCS's ROE is +0.22%, compared to RNLX's ROE of +1.94%. Regarding short-term risk, DOCS is less volatile compared to RNLX. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.
DOCS vs LIFW Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, LIFW has a market cap of 22.4M. Regarding current trading prices, DOCS is priced at $59.38, while LIFW trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas LIFW's P/E ratio is -0.02. In terms of profitability, DOCS's ROE is +0.22%, compared to LIFW's ROE of -3.08%. Regarding short-term risk, DOCS is more volatile compared to LIFW. This indicates potentially higher risk in terms of short-term price fluctuations for DOCS.
DOCS vs VSEE Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, VSEE has a market cap of 22.1M. Regarding current trading prices, DOCS is priced at $59.38, while VSEE trades at $1.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas VSEE's P/E ratio is -14.10. In terms of profitability, DOCS's ROE is +0.22%, compared to VSEE's ROE of -6.10%. Regarding short-term risk, DOCS is less volatile compared to VSEE. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.
DOCS vs VSEEW Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, VSEEW has a market cap of 21.1M. Regarding current trading prices, DOCS is priced at $59.38, while VSEEW trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas VSEEW's P/E ratio is N/A. In terms of profitability, DOCS's ROE is +0.22%, compared to VSEEW's ROE of -6.10%. Regarding short-term risk, DOCS is less volatile compared to VSEEW. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.
DOCS vs MGRX Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, MGRX has a market cap of 17.4M. Regarding current trading prices, DOCS is priced at $59.38, while MGRX trades at $1.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas MGRX's P/E ratio is -0.35. In terms of profitability, DOCS's ROE is +0.22%, compared to MGRX's ROE of -0.73%. Regarding short-term risk, DOCS is less volatile compared to MGRX. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.
DOCS vs BBLN Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, BBLN has a market cap of 14.1M. Regarding current trading prices, DOCS is priced at $59.38, while BBLN trades at $0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas BBLN's P/E ratio is -0.04. In terms of profitability, DOCS's ROE is +0.22%, compared to BBLN's ROE of +4.89%. Regarding short-term risk, DOCS is less volatile compared to BBLN. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.
DOCS vs BFRGW Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, BFRGW has a market cap of 13.9M. Regarding current trading prices, DOCS is priced at $59.38, while BFRGW trades at $1.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas BFRGW's P/E ratio is N/A. In terms of profitability, DOCS's ROE is +0.22%, compared to BFRGW's ROE of -1.63%. Regarding short-term risk, DOCS is less volatile compared to BFRGW. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.
DOCS vs BFRG Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, BFRG has a market cap of 13.8M. Regarding current trading prices, DOCS is priced at $59.38, while BFRG trades at $1.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas BFRG's P/E ratio is -1.86. In terms of profitability, DOCS's ROE is +0.22%, compared to BFRG's ROE of -1.63%. Regarding short-term risk, DOCS is less volatile compared to BFRG. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.
DOCS vs INOV Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, INOV has a market cap of 12.9M. Regarding current trading prices, DOCS is priced at $59.38, while INOV trades at $32.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas INOV's P/E ratio is 16.50. In terms of profitability, DOCS's ROE is +0.22%, compared to INOV's ROE of +0.03%. Regarding short-term risk, DOCS is more volatile compared to INOV. This indicates potentially higher risk in terms of short-term price fluctuations for DOCS.
DOCS vs MSPR Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, MSPR has a market cap of 9.8M. Regarding current trading prices, DOCS is priced at $59.38, while MSPR trades at $1.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas MSPR's P/E ratio is N/A. In terms of profitability, DOCS's ROE is +0.22%, compared to MSPR's ROE of -3.08%. Regarding short-term risk, DOCS is less volatile compared to MSPR. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.
DOCS vs ETAO Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, ETAO has a market cap of 9.8M. Regarding current trading prices, DOCS is priced at $59.38, while ETAO trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas ETAO's P/E ratio is -0.01. In terms of profitability, DOCS's ROE is +0.22%, compared to ETAO's ROE of -13.69%. Regarding short-term risk, DOCS is less volatile compared to ETAO. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.
DOCS vs HCTI Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, HCTI has a market cap of 7.8M. Regarding current trading prices, DOCS is priced at $59.38, while HCTI trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas HCTI's P/E ratio is -0.02. In terms of profitability, DOCS's ROE is +0.22%, compared to HCTI's ROE of -23.25%. Regarding short-term risk, DOCS is less volatile compared to HCTI. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.
DOCS vs HLTH Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, HLTH has a market cap of 6.9M. Regarding current trading prices, DOCS is priced at $59.38, while HLTH trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas HLTH's P/E ratio is -0.02. In terms of profitability, DOCS's ROE is +0.22%, compared to HLTH's ROE of -0.88%. Regarding short-term risk, DOCS is less volatile compared to HLTH. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.
DOCS vs ZCMD Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, ZCMD has a market cap of 5.8M. Regarding current trading prices, DOCS is priced at $59.38, while ZCMD trades at $1.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas ZCMD's P/E ratio is -9.33. In terms of profitability, DOCS's ROE is +0.22%, compared to ZCMD's ROE of -0.03%. Regarding short-term risk, DOCS is less volatile compared to ZCMD. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.
DOCS vs UPH Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, UPH has a market cap of 5.3M. Regarding current trading prices, DOCS is priced at $59.38, while UPH trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas UPH's P/E ratio is -0.07. In terms of profitability, DOCS's ROE is +0.22%, compared to UPH's ROE of -1.05%. Regarding short-term risk, DOCS is less volatile compared to UPH. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.
DOCS vs ACON Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, ACON has a market cap of 4.4M. Regarding current trading prices, DOCS is priced at $59.38, while ACON trades at $7.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas ACON's P/E ratio is -0.65. In terms of profitability, DOCS's ROE is +0.22%, compared to ACON's ROE of -1.27%. Regarding short-term risk, DOCS is less volatile compared to ACON. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.
DOCS vs PEAR Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, PEAR has a market cap of 4.1M. Regarding current trading prices, DOCS is priced at $59.38, while PEAR trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas PEAR's P/E ratio is -0.08. In terms of profitability, DOCS's ROE is +0.22%, compared to PEAR's ROE of -0.39%. Regarding short-term risk, DOCS is less volatile compared to PEAR. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.
DOCS vs PEARW Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, PEARW has a market cap of 4.1M. Regarding current trading prices, DOCS is priced at $59.38, while PEARW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas PEARW's P/E ratio is -0.00. In terms of profitability, DOCS's ROE is +0.22%, compared to PEARW's ROE of -0.39%. Regarding short-term risk, DOCS is less volatile compared to PEARW. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.
DOCS vs OTRK Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, OTRK has a market cap of 4M. Regarding current trading prices, DOCS is priced at $59.38, while OTRK trades at $0.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas OTRK's P/E ratio is -0.03. In terms of profitability, DOCS's ROE is +0.22%, compared to OTRK's ROE of -2.70%. Regarding short-term risk, DOCS is less volatile compared to OTRK. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.
DOCS vs EUDAW Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, EUDAW has a market cap of 3.7M. Regarding current trading prices, DOCS is priced at $59.38, while EUDAW trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas EUDAW's P/E ratio is N/A. In terms of profitability, DOCS's ROE is +0.22%, compared to EUDAW's ROE of +3.05%. Regarding short-term risk, DOCS is less volatile compared to EUDAW. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.
DOCS vs FOXO Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, FOXO has a market cap of 3.3M. Regarding current trading prices, DOCS is priced at $59.38, while FOXO trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas FOXO's P/E ratio is -0.02. In terms of profitability, DOCS's ROE is +0.22%, compared to FOXO's ROE of -0.01%. Regarding short-term risk, DOCS is less volatile compared to FOXO. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.
DOCS vs CMAX Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, CMAX has a market cap of 1.6M. Regarding current trading prices, DOCS is priced at $59.38, while CMAX trades at $0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas CMAX's P/E ratio is -0.00. In terms of profitability, DOCS's ROE is +0.22%, compared to CMAX's ROE of +30.94%. Regarding short-term risk, DOCS is less volatile compared to CMAX. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.
DOCS vs WORX Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, WORX has a market cap of 1.5M. Regarding current trading prices, DOCS is priced at $59.38, while WORX trades at $0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas WORX's P/E ratio is -0.47. In terms of profitability, DOCS's ROE is +0.22%, compared to WORX's ROE of -0.32%. Regarding short-term risk, DOCS is more volatile compared to WORX. This indicates potentially higher risk in terms of short-term price fluctuations for DOCS.
DOCS vs LIFWZ Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, LIFWZ has a market cap of 1.3M. Regarding current trading prices, DOCS is priced at $59.38, while LIFWZ trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas LIFWZ's P/E ratio is N/A. In terms of profitability, DOCS's ROE is +0.22%, compared to LIFWZ's ROE of -3.08%. Regarding short-term risk, DOCS is more volatile compared to LIFWZ. This indicates potentially higher risk in terms of short-term price fluctuations for DOCS.
DOCS vs WGSWW Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, WGSWW has a market cap of 1.2M. Regarding current trading prices, DOCS is priced at $59.38, while WGSWW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas WGSWW's P/E ratio is N/A. In terms of profitability, DOCS's ROE is +0.22%, compared to WGSWW's ROE of -0.17%. Regarding short-term risk, DOCS is less volatile compared to WGSWW. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.
DOCS vs OTRKP Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, OTRKP has a market cap of 1.1M. Regarding current trading prices, DOCS is priced at $59.38, while OTRKP trades at $0.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas OTRKP's P/E ratio is -0.08. In terms of profitability, DOCS's ROE is +0.22%, compared to OTRKP's ROE of -2.70%. Regarding short-term risk, DOCS is less volatile compared to OTRKP. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.
DOCS vs ICCT Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, ICCT has a market cap of 585.3K. Regarding current trading prices, DOCS is priced at $59.38, while ICCT trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas ICCT's P/E ratio is N/A. In terms of profitability, DOCS's ROE is +0.22%, compared to ICCT's ROE of +20.01%. Regarding short-term risk, DOCS is less volatile compared to ICCT. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.
DOCS vs KERN Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, KERN has a market cap of 162.3K. Regarding current trading prices, DOCS is priced at $59.38, while KERN trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas KERN's P/E ratio is -0.01. In terms of profitability, DOCS's ROE is +0.22%, compared to KERN's ROE of -2.22%. Regarding short-term risk, DOCS is less volatile compared to KERN. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.
DOCS vs KERNW Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, KERNW has a market cap of 162.3K. Regarding current trading prices, DOCS is priced at $59.38, while KERNW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas KERNW's P/E ratio is -0.00. In terms of profitability, DOCS's ROE is +0.22%, compared to KERNW's ROE of -2.22%. Regarding short-term risk, DOCS is less volatile compared to KERNW. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.
DOCS vs MSPRZ Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, MSPRZ has a market cap of 86.1K. Regarding current trading prices, DOCS is priced at $59.38, while MSPRZ trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas MSPRZ's P/E ratio is N/A. In terms of profitability, DOCS's ROE is +0.22%, compared to MSPRZ's ROE of -3.08%. Regarding short-term risk, DOCS is more volatile compared to MSPRZ. This indicates potentially higher risk in terms of short-term price fluctuations for DOCS.
DOCS vs LIFWW Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, LIFWW has a market cap of 60.1K. Regarding current trading prices, DOCS is priced at $59.38, while LIFWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas LIFWW's P/E ratio is N/A. In terms of profitability, DOCS's ROE is +0.22%, compared to LIFWW's ROE of -3.08%. Regarding short-term risk, DOCS is more volatile compared to LIFWW. This indicates potentially higher risk in terms of short-term price fluctuations for DOCS.
DOCS vs CMAXW Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, CMAXW has a market cap of 36.4K. Regarding current trading prices, DOCS is priced at $59.38, while CMAXW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas CMAXW's P/E ratio is N/A. In terms of profitability, DOCS's ROE is +0.22%, compared to CMAXW's ROE of +30.94%. Regarding short-term risk, DOCS is more volatile compared to CMAXW. This indicates potentially higher risk in terms of short-term price fluctuations for DOCS.
DOCS vs ACONW Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, ACONW has a market cap of 14.3K. Regarding current trading prices, DOCS is priced at $59.38, while ACONW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas ACONW's P/E ratio is N/A. In terms of profitability, DOCS's ROE is +0.22%, compared to ACONW's ROE of -1.27%. Regarding short-term risk, DOCS is less volatile compared to ACONW. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.
DOCS vs MSPRW Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, MSPRW has a market cap of 9.3K. Regarding current trading prices, DOCS is priced at $59.38, while MSPRW trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas MSPRW's P/E ratio is N/A. In terms of profitability, DOCS's ROE is +0.22%, compared to MSPRW's ROE of -3.08%. Regarding short-term risk, DOCS is more volatile compared to MSPRW. This indicates potentially higher risk in terms of short-term price fluctuations for DOCS.
DOCS vs UTRS Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, UTRS has a market cap of 888. Regarding current trading prices, DOCS is priced at $59.38, while UTRS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas UTRS's P/E ratio is N/A. In terms of profitability, DOCS's ROE is +0.22%, compared to UTRS's ROE of -1.11%. Regarding short-term risk, DOCS is more volatile compared to UTRS. This indicates potentially higher risk in terms of short-term price fluctuations for DOCS.
DOCS vs CSLT Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, CSLT has a market cap of 0. Regarding current trading prices, DOCS is priced at $59.38, while CSLT trades at $2.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas CSLT's P/E ratio is -37.27. In terms of profitability, DOCS's ROE is +0.22%, compared to CSLT's ROE of -0.42%. Regarding short-term risk, DOCS is more volatile compared to CSLT. This indicates potentially higher risk in terms of short-term price fluctuations for DOCS.
DOCS vs MTBCP Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, MTBCP has a market cap of 0. Regarding current trading prices, DOCS is priced at $59.38, while MTBCP trades at $26.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas MTBCP's P/E ratio is N/A. In terms of profitability, DOCS's ROE is +0.22%, compared to MTBCP's ROE of +0.21%. Regarding short-term risk, DOCS is more volatile compared to MTBCP. This indicates potentially higher risk in terms of short-term price fluctuations for DOCS.
DOCS vs CNVY Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, CNVY has a market cap of 0. Regarding current trading prices, DOCS is priced at $59.38, while CNVY trades at $10.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas CNVY's P/E ratio is -71.50. In terms of profitability, DOCS's ROE is +0.22%, compared to CNVY's ROE of -0.02%. Regarding short-term risk, DOCS is more volatile compared to CNVY. This indicates potentially higher risk in terms of short-term price fluctuations for DOCS.
DOCS vs SMFRW Comparison
DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DOCS stands at 11.2B. In comparison, SMFRW has a market cap of 0. Regarding current trading prices, DOCS is priced at $59.38, while SMFRW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DOCS currently has a P/E ratio of 53.52, whereas SMFRW's P/E ratio is N/A. In terms of profitability, DOCS's ROE is +0.22%, compared to SMFRW's ROE of -0.17%. Regarding short-term risk, DOCS is less volatile compared to SMFRW. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.